The experiment compared three spheroid models: HepG2 hepatocellular carcinoma cells alone, LX-2 hepatic stellate cells alone, and a 1:1 coculture containing both cell types. Each well received a total of 50,000 cells, with cocultures containing 25,000 cells of each type. Spheroids formed through spontaneous self-assembly in agar-coated 96-well U-bottom plates and were followed for 96 hours. The study combined longitudinal phase-contrast imaging and ImageJ-based morphometry with scanning electron microscopy, flow cytometry, biochemical assays, and a CellTiter-Glo 3D viability assay.

HepG2 monoculture spheroids had a projected area 4.6 times greater than coculture spheroids and 4.8 times greater than LX-2 spheroids at 96 hours, with both comparisons reported as statistically significant. Projected area in LX-2 and coculture spheroids declined by 72% and 71.7%, respectively, during the first 24 hours. By 96 hours, area had fallen 80.42% in LX-2 spheroids and 77.9% in coculture spheroids, while the 21.9% decline in HepG2 spheroids was not statistically significant.

Other shape measurements also distinguished the models. At 96 hours, mean circularity was 0.1373 for HepG2 spheroids, 0.4045 for LX-2 spheroids, and 0.4112 for cocultures; HepG2 values were significantly lower than those of both comparison models. Perimeter reductions from 2 to 96 hours were 77.0% for LX-2 and 70.8% for coculture spheroids, compared with a nonsignificant 23.8% reduction for HepG2. An image-derived optical compaction index also rose significantly over time in LX-2 and coculture spheroids. The researchers cautioned that this index was an indirect measure of apparent optical compaction, not a direct measurement of cellular density, extracellular matrix content, or mechanical stiffness.

Scanning electron microscopy after 96 hours showed a compact, continuous surface on LX-2 spheroids and a rough, porous surface on HepG2 spheroids. Coculture spheroids had an intermediate appearance, with a more continuous external organization than HepG2 spheroids but remaining surface irregularities. These observations were consistent with the quantitative morphometry, although the study did not directly measure extracellular matrix mechanics or establish which processes caused the structural differences.

Cell-death measurements were broadly similar for viable, early-apoptotic, and late-apoptotic populations. Coculture spheroids had a lower mean proportion of propidium-iodide-positive cells than HepG2 spheroids, but that pairwise comparison did not reach statistical significance. The percentage of active-caspase-3-positive cells did not differ significantly among models. Fluorescence intensity did, however, because cocultures had lower active-caspase-3 signal than HepG2 spheroids. When cells in cocultures were operationally separated by hepatocyte nuclear factor 4 alpha expression, the HepG2-like population had approximately 28% lower signal than HepG2 monocultures, while the putative LX-2-like population had approximately 76% lower signal than LX-2 monocultures. Because caspase-3 activation is transient, the fluorescence measurements do not by themselves establish a lower rate of apoptosis.

Biochemical testing found that intracellular LDH activity did not differ significantly among models, while extracellular LDH activity was highest in HepG2 spheroids, intermediate in cocultures, and lowest in LX-2 spheroids. LDH release normalized to total measurable LDH did not differ significantly between HepG2 and coculture spheroids, so the normalized result did not independently confirm better membrane preservation in cocultures. Extracellular lactate concentrations in conditioned medium were highest in LX-2 spheroids, intermediate in cocultures, and lowest in HepG2 spheroids. These values were not normalized to cell number, DNA, protein content, or biomass and therefore represented concentrations in the medium rather than cell-specific lactate production rates.

Flow cytometry also identified stromal-associated matrix signals. Approximately 24% of coculture singlet cells were alpha-smooth muscle actin-positive after 96 hours, although marker-defined fractions did not provide an exact measurement of cellular composition. Collagen type I alpha 1-associated fluorescence was higher in cocultures than in HepG2 monocultures and was concentrated in the alpha-smooth muscle actin-positive compartment. This supported the presence of a collagen-producing, activated-like stromal phenotype, but the experiment did not directly quantify collagen deposition, extracellular matrix organization, or tissue stiffness.

Coculture spheroids retained greater viability than HepG2 spheroids at 15 and 25 micromolar sorafenib, and concentration-response analysis produced an estimated IC30 approximately three times higher than that of HepG2 monocultures. The findings associate LX-2 inclusion with lower sorafenib sensitivity rather than complete resistance, because coculture viability declined at the highest concentrations tested. The study did not measure intracellular drug accumulation, penetration, matrix stiffness, or specific signaling pathways, so it could not determine whether reduced sensitivity arose from structural barriers, paracrine signals, or both.

The principal limitation was the use of established HepG2 and LX-2 cell lines, which do not reproduce the genetic, phenotypic, or interpatient diversity of primary tumors and stromal populations. LX-2 cells also have a constitutively activated-like phenotype and cannot represent the full range of hepatic stellate cell states found in human liver tumors. The results therefore characterize this defined in vitro system rather than clinical sorafenib response in people with hepatocellular carcinoma.

Subject of Research: Effects of LX-2 hepatic stellate cells on 3D HepG2 spheroid architecture, biomarkers, metabolism, and sorafenib sensitivity

Article Title: Hepatic stellate cells promote structural and functional remodeling of three-dimensional hepatocellular carcinoma coculture spheroids

Article References: Obelar, J., Vasconcellos, J. G., do Nascimento, N. B., de Sousa, A. C., Giehl, M., Simões Fischer, B., de Souza Ferreira, J., de Oliveira, J., Trindade, V. M. T., & Guma, F. T. C. R. (2026). Hepatic stellate cells promote structural and functional remodeling of three-dimensional hepatocellular carcinoma coculture spheroids. Molecular Biology Reports, 53(1), Article 1566. https://doi.org/10.1007/s11033-026-12715-9

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12715-9

Keywords: hepatocellular carcinoma, hepatic stellate cells, three-dimensional culture, spheroids, extracellular matrix, COL1A1, sorafenib, cell death, tumor microenvironment, Hepatic, stellate, cells

Researchers generated NHSL3 knockout clones in both cell lines using paired Cas9 nickase editing and obtained data from three independent biological experiments. In Huh-7 cells, NHSL3 loss increased sensitivity to sorafenib: the reported 24-hour half-maximal inhibitory concentration decreased from 13.4 µM to 5.8 µM. The knockout was associated with enrichment in G1 phase, a reduced S-phase fraction, and impaired clonogenic growth. Wound-closure and transwell assays also showed delayed wound closure and reduced migration. Invasion results varied according to sorafenib exposure and the duration of the assay.

The genotype-dependent sorafenib response was more modest in Hep3B cells and appeared at 48 hours. NHSL3 loss in that model was nevertheless associated with reduced clonogenic growth, as well as lower migration and invasion under vehicle-treated conditions. These findings indicate that the growth and motility phenotypes were more consistent across the two cell backgrounds than the drug-response phenotype. The study therefore does not support treating the effect of NHSL3 loss on sorafenib sensitivity as identical in every HCC cell model.

Molecular analyses in Huh-7 cells identified changes associated with epithelial-mesenchymal transition-related protein remodeling, including a blunted E-cadherin response to sorafenib and increased vimentin and N-cadherin levels. NHSL3 loss was also associated with lower basal phosphorylated RAF1 levels and with YAP/TAZ responses that depended on confluence and sorafenib exposure. The available report is limited to cell models and the abstract; it does not establish the relevance of these observations to clinical treatment responses or patient outcomes.

Subject of Research: NHSL3 knockout effects on sorafenib response, growth, and motility in hepatocellular carcinoma cell models

Article Title: NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models

Article References: Yıldız, G., Karabulut, S., & Dinçer, T. (2026). NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models. Molecular Biology Reports, 53(1), Article 1591. https://doi.org/10.1007/s11033-026-12760-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12760-4

Keywords: NHSL3, hepatocellular carcinoma, sorafenib, Huh-7 cells, Hep3B cells, cell models, cancer cell biology, migration, clonogenic growth, knockout, modulates, response

The review, led by Tao Huang and Qiaoying Li of Southwest Medical University in Sichuan, China, together with colleagues, takes an unusually rigorous approach to a field notorious for loose claims. Rather than accepting every published association between fibroblasts and drug failure, the authors graded the evidence according to strict criteria: whether a defined drug was actually being administered, whether treatment-related outcomes were measured, and—critically—whether blocking the fibroblast pathway functionally restored drug sensitivity in experiments. Only mechanisms passing these tests earn the label of true resistance mechanisms. The distinction matters, because fibroblasts drive tumor progression in many ways, and progression is not the same thing as resistance to therapy.

Cancer-associated fibroblasts arise largely from hepatic stellate cells, the liver’s resident vitamin A-storing cells that normally lie dormant until injury wakes them. In chronic liver disease they become the workhorses of fibrosis, laying down scar tissue. When a tumor takes root in this scarred landscape, the activated fibroblasts multiply and diversify into subtypes with very different personalities: inflammatory fibroblasts that pump out signaling molecules, myofibroblastic fibroblasts that build dense extracellular matrix, and even antigen-presenting fibroblasts that can interact directly with immune cells. Single-cell and spatial transcriptomic studies have mapped these populations in hepatocellular carcinoma in increasing detail, and the picture that emerges is of a tumor wrapped in a living, communicating stroma.

The most convincing resistance story in the review concerns a fibroblast-secreted protein called SPP1, also known as osteopontin. When patients receive sorafenib or lenvatinib, fibroblasts respond by secreting SPP1, which binds integrins on the surface of tumor cells and activates a bypass signaling route through protein kinase C alpha. In effect, the drug blocks the main growth pathway while the fibroblasts quietly open a side door. Experiments in which SPP1 was knocked down genetically or blocked pharmacologically restored the tumor cells’ sensitivity to the kinase inhibitors, satisfying the review’s strictest evidentiary standard. This is no longer a correlation; it is a mechanism with a demonstrated rescue experiment behind it.

A second well-supported pathway involves the chemokine CXCL12. Fibroblast-derived CXCL12 signals through its receptor CXCR4 on hepatocellular carcinoma cells, triggering upregulation of a molecule called FOLR1, the folate receptor 1. The result is a reduction in the apoptosis—the programmed cell death—that sorafenib is supposed to induce. Independent work using quantitative proteomics had already implicated FOLR1 in sorafenib resistance through activation of autophagy, the cellular recycling program that helps stressed cancer cells survive. When researchers interfered with the CXCL12–CXCR4 axis, including with the CXCR4 antagonist plerixafor, sorafenib’s killing power returned.

The third mechanistically resolved pathway is perhaps the most elegant. Fibroblasts deposit fibronectin bearing an extra domain A, an embryonic splice variant of the matrix protein that is largely absent from healthy adult liver but abundant in tumors and fibrotic tissue. This oncofetal form of fibronectin, long recognized as a molecular marker of hepatocellular carcinoma, appears to signal through the innate immune receptor Toll-like receptor 4 on tumor cells, activating the transcription factor NF-κB and the metabolic enzyme SHMT1. The consequence is a shift in redox metabolism: the cancer cells adapt to the oxidative stress that sorafenib generates and simply keep going. Blocking this axis restores drug sensitivity, completing the causal chain from fibroblast product to receptor to transcription factor to metabolic enzyme to survival.

When the review turns to immunotherapy, the evidence becomes more circumstantial, and the authors are careful to say so. Periostin-positive fibroblasts, a stromal subset identified in patient tumors, are associated with recruitment of macrophages through the interleukin-6 signaling pathway, elevated SPP1 expression within those macrophages, physical exclusion of immune cells from the tumor, and reduced responsiveness to immune checkpoint inhibitors. The proposed chain of events is coherent: fibroblasts build a stromal-immune barrier that keeps cytotoxic T cells at arm’s length, so the checkpoint drug has no targets to reactivate. But unlike the tyrosine kinase inhibitor stories, no experiment has yet shown that selectively reversing this specific periostin-positive fibroblast program restores immunotherapy responses in hepatocellular carcinoma. The association is strong; the causal proof is pending.

That gap reflects a broader and sobering lesson from the fibroblast field. In pancreatic cancer, the classic cautionary tale, researchers depleted carcinoma-associated fibroblasts in mouse models and expected tumors to shrink. Instead, the tumors became more aggressive and the animals died faster, revealing that some fibroblasts restrain cancer rather than feed it. The review emphasizes that fibroblast heterogeneity makes blanket depletion strategies dangerous: eliminating the wrong subtype could dismantle the stromal barriers that contain the tumor while sparing the very cells that drive resistance. The field’s central question has accordingly shifted from whether to target fibroblasts to which ones, when, and how.

Translational efforts are already adapting to this nuance. Nanoparticle systems have been engineered to deliver small interfering RNA directly to fibroblasts, silencing stromal targets such as microfibril-associated protein 5 in antistromal therapy for hepatocellular carcinoma. Other platforms exploit fibroblast biology for drug delivery: lipid nanoparticles that transform in size in response to fibroblast activation protein activity, releasing their payload deep within fibrotic tumor tissue, and dual-targeting nanoparticles that simultaneously remodel the stroma and reprogram immune cells. CXCR4 antagonist-loaded nanoparticles have been shown to reprogram the tumor microenvironment and enhance immunotherapy in preclinical models. Even diagnostic imaging is joining in, with fibroblast activation protein-targeted PET tracers now being tested to monitor liver fibrosis and tumor burden, potentially allowing clinicians to stratify patients by the stromal character of their tumors before choosing a therapy.

The review’s authors, funded by the National Natural Science Foundation of China, frame their conclusions as a call for discipline in a rapidly growing literature. The fibroblast field has generated an abundance of associations—extracellular vesicles carrying resistance-promoting microRNAs, exosomal signals that decrease sorafenib sensitivity, fibroblast-derived growth factors that sustain tumor cells through metabolic crosstalk—but only a handful of mechanisms in hepatocellular carcinoma have been validated with the combination of defined drug exposure, treatment outcomes, and functional rescue. SPP1, CXCL12–FOLR1, and fibronectin extra domain A now stand on the firmest ground, each with a plausible route to clinical intervention. For patients whose liver cancers stop responding to the current arsenal, the hope is that the next generation of treatments will not merely attack the tumor harder, but will disarm the cellular accomplices that have been quietly protecting it all along.

Subject of Research: Cancer-associated fibroblast mechanisms of therapeutic resistance in hepatocellular carcinoma

Article Title: Cancer-associated fibroblasts in therapeutic resistance of hepatocellular carcinoma: evidence, mechanisms, and translational implications

Article References: Huang, T., Li, Q., Yu, Z., Wu, Z., Cheng, H., Zhang, X., Yang, L., & Wang, S. (2026). Cancer-associated fibroblasts in therapeutic resistance of hepatocellular carcinoma: evidence, mechanisms, and translational implications. Medical Oncology, 43(11), Article 314. https://doi.org/10.1007/s12032-026-03435-y

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03435-y

Keywords: hepatocellular carcinoma, cancer-associated fibroblasts, therapeutic resistance, tyrosine kinase inhibitors, immune checkpoint inhibitors, sorafenib, lenvatinib, SPP1, CXCL12, fibronectin extra domain A, tumor microenvironment, spatial transcriptomics

The three compounds, labeled 5a, 5b and 5c, follow the classic donor–π–acceptor (D–π–A) blueprint that underlies many modern organic dyes. Diphenylamine serves as the electron-rich donor, a thiazole heterocycle acts as the rigid π-conjugated bridge, and a terminal benzoyl acrylonitrile group functions as the electron acceptor. The only variable across the series is the para-substituent on the terminal benzoyl ring: nitro in 5a, cyano in 5b and carboxylic acid in 5c. The molecules were assembled through a Knoevenagel condensation between a formylated diphenylamino-thiazole precursor and three phenacyl cyanide derivatives, with yields ranging from 68.8 to 78.4 percent, and were confirmed by infrared, nuclear magnetic resonance and mass spectrometry.

Quantum-chemical modelling formed the theoretical backbone of the study. The team optimized each structure using the B3LYP hybrid functional with a 6-311G(++) basis set and simulated absorption and emission spectra with time-dependent DFT, employing a polarizable continuum solvation model to mimic DMSO. The calculations revealed near-planar geometries and a clear division of electronic labor: the highest occupied molecular orbitals sat on the diphenylamino-thiazole donor, while the lowest unoccupied orbitals extended toward the electron-withdrawing termini. The nitro derivative 5a showed the smallest frontier orbital gap in the ground state, 4.97 electron-volts, compared with 5.11 eV for the cyano compound and 5.13 eV for the carboxylic acid, and its gap contracted most dramatically upon excitation, falling to 3.68 eV—a hallmark of strong intramolecular charge transfer.

The experimental photophysics tracked the computations closely. In solution, all three dyes displayed an intense low-energy absorption band assigned to charge-transfer excitation, with maxima that shifted to longer wavelengths as solvent polarity increased. Compound 5a was the most solvent-sensitive, its absorption maximum moving 34 nanometers between tetrahydrofuran and DMSO, while 5b and 5c shifted only 13 and 14 nanometers respectively. Emission followed the same logic: 5a glowed furthest into the red, peaking at 613 nanometers in DMSO, whereas the cyano and carboxylic analogues emitted at shorter wavelengths. The carboxylic acid derivative 5c posted the largest Stokes shifts of the series, roughly 7,100 to 7,200 per centimeter, which the authors attribute to hydrogen bonding and extensive excited-state relaxation.

Fluorescence efficiency told a subtler story. Despite its strong charge-transfer character, the nitro compound 5a showed a slightly reduced quantum yield of 0.678, likely because nitro groups open nonradiative decay channels. The cyano derivative 5b achieved the highest quantum yield of the series at 0.748, suggesting that moderate electron withdrawal sustains efficient charge transfer while suppressing competing relaxation pathways. Time-dependent DFT reproduced these trends, attributing the dominant visible emission in all three dyes to HOMO-to-LUMO charge-transfer transitions, with the calculated emission maximum of 5a red-shifted to 646 nanometers, consistent with the ordering of acceptor strength from nitro to cyano to carboxyl.

The biological results are where the study takes on its most striking dimension. Using the MTT assay, the team tested the dyes against HepG2 liver cancer, MCF-7 breast cancer and HT-29 colon cancer cells, alongside normal WI38 fibroblasts as a selectivity control. All three compounds proved more toxic to cancer cells than to normal fibroblasts, with selectivity indices generally between two and three. The cyano compound 5b emerged as the standout against HT-29 colon cancer cells, halting growth at a concentration of 21.05 micromolar while leaving normal cells largely unharmed up to 77.44 micromolar—a therapeutic window the authors note compares favorably with the reference drug doxorubicin in terms of selectivity. Compound 5c was most active against MCF-7 breast cancer cells at 28.46 micromolar, while 5a showed more uniform but weaker activity across the panel.

The mechanism behind this cytotoxicity remains hypothetical, and the authors are careful to frame it that way. They propose that the heteroaromatic scaffolds may trigger apoptosis through mitochondrial membrane depolarization, cytochrome c release and caspase activation, or alternatively arrest the cell cycle by inhibiting cyclin-dependent kinases. The strong charge-transfer absorption of the dyes also raises the possibility of electron-transfer reactions that elevate intracellular oxidative stress, a vulnerability that cancer cells, already living near their redox limits, are poorly equipped to tolerate. None of these mechanisms was directly tested; the authors recommend follow-up flow cytometry, caspase assays and reactive oxygen species measurements to confirm the pathways.

More concrete evidence came from the kinase experiments. Vascular endothelial growth factor receptor 2, or VEGFR-2, is a validated anticancer target because blocking it starves tumors of their blood supply. In vitro assays showed that all three chromophores inhibit the enzyme at sub-micromolar concentrations, with the nitro compound 5a the most potent at 0.44 micromolar, followed by 5c at 0.59 micromolar and 5b at 0.81 micromolar—placing the entire series in the same potency range as the clinical drug sorafenib. Molecular docking against the VEGFR-2 crystal structure (PDB entry 1YWN) lent mechanistic texture to these numbers. Compound 5a achieved the best binding score, minus 6.59 kilocalories per mole, forming hydrogen bonds with the hinge residues Cys917 and Cys1043 through its nitro and olefinic groups. Compound 5c, though slightly weaker in score, showed the most stable docked pose with three distinct bonding interactions, while 5b relied on two acceptor-type contacts with Arg831 and Lys856. Sorafenib itself docked at minus 6.25 kilocalories per mole with a higher conformational instability than the new ligands.

To verify that the docked poses were not computational artifacts, the team ran a 100-nanosecond molecular dynamics simulation on the VEGFR-2–5a complex. The system equilibrated within the first 10 nanoseconds and remained stable thereafter, with the binding-site residues Cys917 and Cys1043 showing minimal fluctuation and two to three hydrogen bonds persisting between ligand and protein throughout the trajectory. The radius of gyration stayed constant, indicating the protein remained compact, and MM-PBSA free-energy calculations returned favorable negative values driven by van der Waals and electrostatic terms—together confirming that the complex is both dynamically and thermodynamically stable.

The authors caution that docking scores are qualitative guides rather than quantitative predictions of biological activity, and that factors such as solubility and membrane permeability also shape cellular outcomes. They likewise note that structure–activity conclusions drawn from only three analogues are necessarily preliminary. Even so, the study delivers a coherent structure–property framework: acceptor strength orders the frontier orbital gaps, the solvatochromic response, the emission wavelengths and, intriguingly, the biological profile. The nitro group maximizes charge transfer and kinase affinity, the cyano group maximizes fluorescence yield and colon-cancer selectivity, and the carboxylic acid group maximizes Stokes shift and breast-cancer activity. For researchers hunting molecules that can image a tumor and attack it at the same time, this diphenylamino-thiazole platform offers a rare and tunable starting point.

Subject of Research: Donor–π–acceptor diphenylamino-thiazole fluorescent chromophores with tunable intramolecular charge transfer, cytotoxic activity and VEGFR-2 kinase inhibition

Article Title: Molecular modelling and cytotoxic activity of donor-π-acceptor fluorescent diphenylamino-thiazole chromophores

Article References: Albalawi, S., & Abualnaja, M. M. (2026). Molecular modelling and cytotoxic activity of donor-π-acceptor fluorescent diphenylamino-thiazole chromophores. Journal of Saudi Chemical Society, 30(3), Article 28. https://doi.org/10.1007/s44442-026-00063-z

Image Credits: AI Generated

DOI: 10.1007/s44442-026-00063-z

Keywords: fluorescent chromophores, donor-π-acceptor, diphenylamine, thiazole, intramolecular charge transfer, TD-DFT, solvatochromism, cytotoxicity, HT-29 colon cancer, VEGFR-2 kinase, molecular docking, sorafenib

The two ingredients are sorafenib, a multikinase inhibitor used clinically against liver and other cancers, and curcumin, the polyphenolic compound extracted from turmeric rhizome that has long attracted interest for its anticancer properties. Both drugs share a frustrating limitation: patients frequently develop resistance to sorafenib after prolonged treatment, while curcumin suffers from poor solubility and weak fluorescence. The researchers dissolved the two molecules in dimethyl sulfoxide and injected the solution dropwise into water. As the proportion of water rose, the molecules spontaneously clustered into spherical nanoparticles roughly 286 nanometers in diameter, with a narrow size distribution and a strongly negative surface charge consistent with good biocompatibility.

What makes these particles remarkable is that neither drug fluoresces meaningfully on its own. Free curcumin actually loses its weak emission when it aggregates, a phenomenon known as aggregation-caused quenching, and sorafenib is similarly dark. Yet when the two co-assemble, the resulting nanoparticles emit bright light, a behavior the authors describe as a 0 + 0 > 2 fluorescence effect and term pharmaceutical dots-induced emission. Spectroscopic analysis revealed why: the pyridine ring of sorafenib stacks against the aromatic rings of curcumin through pi-pi interactions, while hydrogen bonds form between curcumin’s ketonic groups and sorafenib’s nitrogen atoms. Molecular dynamics simulations running over 50 nanoseconds showed the drugs first clustering separately and then merging into a stable core-shell architecture, with fluorine and chlorine atoms from sorafenib concentrated in the core and curcumin woven throughout.

The practical advantages of this carrier-free design are substantial. Traditional nanocarriers often achieve drug loadings below 10 percent because the carrier material dilutes the payload, but the self-assembled particles reached encapsulation efficiencies above 98 percent for both drugs, with sorafenib loading at 78 percent and curcumin at 14 percent. The particles also exhibited a large Stokes shift of 130 nanometers, which minimizes self-absorption and background autofluorescence, and their emission position stayed fixed across excitation wavelengths, a property that simplifies high-precision bioimaging. Stability tests in serum showed no change in particle size or fluorescence over extended periods, and in tumor-bearing mice the nanoparticles produced strong detectable signals in the lungs where a simple drug mixture produced none.

But the imaging capability turned out to be only the opening act. When the researchers treated breast cancer 4T1 cells and human liver cancer MHCC-97H cells with the nanoparticles, transmission electron microscopy revealed something unexpected: lysosomes and mitochondria, the cell’s digestive and energy-producing organelles, migrated toward the nucleus and clustered tightly around it. In untreated cells, mitochondria sat an average of 242 nanometers from one another and more than 225 nanometers from the nucleus. After treatment, those distances collapsed to roughly 17, 22 and 45 nanometers respectively, close enough to constitute direct interorganelle contact sites. Structured illumination microscopy and confocal imaging of the organelle marker proteins LAMP1, TOMM20 and Lamin B1 confirmed the same tripartite lysosome-mitochondrion-nucleus contacts in both cell lines and later in metastatic lung tissue.

To understand what these contacts accomplish, the team turned to proteomics. Quantitative mass spectrometry identified 2,244 differentially expressed proteins after nanoparticle treatment, with gene ontology analysis showing that the altered proteins concentrated in the nucleus, cytoplasm and mitochondrion. Upregulated proteins enriched in mitochondrial functions such as oxidative phosphorylation and NADH dehydrogenase activity, while downregulated proteins clustered around nuclear processes including DNA replication, cell cycle transitions and epigenetic regulation. Cross-referencing the differentially expressed proteins against survival genes from breast cancer patient data pointed to a single nuclear suspect: histone deacetylase 2, or HDAC2, an epigenetic enzyme whose overexpression is associated with poor outcomes and metastatic progression in breast cancer patients.

The mechanistic picture that emerged links organelle geometry to gene regulation. Mitochondria are the primary generators of reactive oxygen species, and lysosomes can amplify mitochondrial ROS production. By herding both organelles against the nuclear membrane, the nanoparticles appear to deliver a concentrated burst of ROS directly into the nucleus. Flow cytometry of isolated nuclear fractions confirmed elevated nuclear ROS after treatment, and the signal scaled with both dose and time. That nuclear ROS, the researchers found, suppresses HDAC2. When they scavenged ROS with N-acetylcysteine, HDAC2 expression rebounded; when the nanoparticles were present, ROS climbed and HDAC2 fell again. Conversely, blocking HDAC2 directly with the approved inhibitor vorinostat reproduced the antimigratory effect, confirming HDAC2 as a functional node rather than a bystander.

The downstream consequence is the collapse of epithelial-mesenchymal transition, the cellular program that allows cancer cells to detach, invade and colonize new tissue. Treated cells showed restored E-cadherin, the adhesion molecule lost during metastatic conversion, and reduced Vimentin, the motility marker that rises as cells turn invasive. Wound healing assays told the story in numbers: untreated cells closed a scratch almost completely within 24 hours, free sorafenib slowed closure to about 52 percent, the drug mixture to 34 percent, but the nanoparticles cut it to roughly 11 percent. Transwell invasion assays, western blots and immunofluorescence all corroborated the shift, and the nanoparticles also preserved sorafenib’s original function, suppressing phosphorylation of VEGFR and ERK while additionally sensitizing cells to mitochondrial ferroptosis through effects on GPX4 and DHODH.

In vivo, the strategy proved itself in mouse models of breast cancer lung metastasis. When 4T1 cells pretreated with the nanoparticles were injected into mice, lung weights and histopathology showed dramatically fewer metastatic lesions than with either drug alone. In a therapeutic model using luciferase-labeled 4T1 cells, intravenous dosing every two days for five doses produced significant reductions in tumor burden, metastatic nodule counts and bioluminescent signal compared with paclitaxel, curcumin or sorafenib, and paclitaxel itself has been reported to worsen metastasis in some models. Immunohistochemistry of metastatic lungs confirmed the same molecular signature seen in culture: high E-cadherin, low Vimentin, suppressed HDAC2, and dense perinuclear clusters of lysosomes and mitochondria. Body weights remained stable throughout, and histological and serum chemistry analyses of major organs showed no pathological damage, with liver and kidney markers staying within normal ranges.

The study’s broader significance lies in its demonstration that organelle positioning, not just molecular targeting, can be a therapeutic lever. Cancer cells depend on coordinated communication among lysosomes, mitochondria and the nucleus, yet these tripartite contacts had remained largely unexplored as drug targets. By pairing a kinase inhibitor with a dietary polyphenol in a carrier-free assembly, the researchers achieved simultaneous multi-target action, real-time imaging and a previously uncharacterized nuclear ROS-HDAC2-EMT axis, all without the cytotoxic residues that chemical fluorescent labeling would introduce. The work remains at the preclinical stage, and the specific drug pair was chosen partly for its assembly chemistry, but the concept of converting drug molecules themselves into self-reporting, organelle-orchestrating therapeutics opens a genuinely new direction for antimetastatic drug design, one where the medicine and the microscope share the same molecule.

Subject of Research: A carrier-free supramolecular nanoassembly of sorafenib and curcumin that inhibits tumor metastasis through lysosome-mitochondrion-nucleus contacts and a nuclear ROS-HDAC2-EMT signaling axis

Article Title: A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis

Article References: Wang, R., Zou, L., Mi, D., Wang, C., Song, Z., Liu, T., Zhao, M., Wang, D., & Shi, S. (2026). A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis. Materials Today Bio, 41, Article 103681. https://doi.org/10.1016/j.mtbio.2026.103681

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103681

Keywords: sorafenib, curcumin, self-assembly, nanoparticles, metastasis, lysosome-mitochondria contacts, nuclear ROS, HDAC2, epithelial-mesenchymal transition, pharmaceutical dots, fluorescence imaging, breast cancer

What makes natural killer cells so attractive as an anti-cancer weapon is their biology. Unlike cytotoxic T cells, which must be primed against a specific antigen before they can attack, NK cells are hardwired to detect and destroy transformed tissue on contact, without prior sensitization. They patrol the body constantly, integrating activating and inhibitory signals through a sophisticated array of germline-encoded receptors. When a cell loses the surface expression of major histocompatibility complex class I molecules, a common immune-evasion trick employed by tumors, the inhibitory brakes on NK cells are released and the killer cell delivers its lethal hit through the polarized release of lytic granules containing perforin and granzymes. NK cells also deploy activating receptors such as NKG2D and the natural cytotoxicity receptors NKp30, NKp44, and NKp46, which recognize stress-induced ligands upregulated on malignant cells. Beyond direct killing, they shape the broader immune response by secreting interferon-gamma and tumor necrosis factor alpha, which in turn promote the maturation of dendritic cells and support T cell priming, making them both executioners and orchestrators of antitumor immunity.

The liver, however, is a uniquely hostile arena for these cells. The review devotes considerable attention to the hepatocellular carcinoma tumor microenvironment, describing it as a formidable barrier that systematically disables NK cell function. Chronic exposure to transforming growth factor beta, an immunosuppressive cytokine abundantly produced in cirrhotic and tumor-bearing livers, downregulates activating receptors and blunts cytotoxicity. Persistent hypoxia, a hallmark of rapidly growing tumors with disorganized vasculature, further erodes NK cell metabolism and effector function. Perhaps most strikingly, the review highlights metabolic exhaustion driven by lipid accumulation: tumor cells and their supporting stroma flood the microenvironment with lactic acid and lipids, reprogramming NK cell metabolism and starving the cells of the glycolytic capacity they need to mount an effective attack. Studies cited in the review show that lactate dehydrogenase-associated lactic acid production directly blunts tumor immunosurveillance by both T and NK cells, and that fructose-1,6-bisphosphatase-induced inhibition of glycolysis cripples NK cell function during tumor progression.

The clinical evidence of NK cell dysfunction in liver cancer is equally sobering. Single-cell sequencing studies of human liver tumors have mapped the landscape of infiltrating immune cells and revealed that tumor-resident NK cells are phenotypically and functionally compromised. Tissue-resident CD56-bright NK cells enriched in the adult human liver, characterized by high Eomes and low T-bet expression, show reduced proinflammatory potential compared with their blood counterparts. In patients with hepatocellular carcinoma, myeloid-derived suppressor cells inhibit NK cell activity through the NKp30 receptor, and elevated levels of soluble NKG2D ligands and immunomodulatory molecules such as DKK3 further dampen antitumor responses. Exhaustion markers tell a similar story: NK cells expressing the inhibitory receptors TIGIT, TIM-3, CD96, and programmed death 1 correlate with disease progression in hepatitis B virus-related hepatocellular carcinoma, and high CD96 expression on NK cells predicts poorer prognosis. Downregulation of the PR/SET domain 10 protein has also been implicated as an underlying mechanism of NK cell dysfunction in these patients.

Against this backdrop, the review maps out the therapeutic strategies now being pursued to restore or supercharge NK cell activity. The most straightforward approach is cytokine-supported adoptive transfer: NK cells harvested from patients or healthy donors are expanded ex vivo using cytokines such as interleukin-15 and interleukin-21, then infused back in large numbers. Interleukin-15 has shown particular promise, with experimental work demonstrating that it can overcome hepatocellular carcinoma-induced NK cell dysfunction. The foundational proof of concept came from early clinical studies showing successful adoptive transfer and in vivo expansion of haploidentical NK cells in patients with cancer, and more recent trials have extended the approach to liver cancer specifically. A phase I trial of NK cell infusion in patients with recurrent hepatocellular carcinoma after liver transplantation reported that the treatment was well tolerated and showed preliminary efficacy, while an open-label phase I study protocol is testing adoptive immunotherapy with NK cells derived from peripheral blood CD34-positive stem cells to prevent recurrence after curative hepatectomy.

Genetic engineering has pushed the field considerably further. Chimeric antigen receptor-engineered NK cells, or CAR-NK cells, are equipped with synthetic receptors that redirect their killing capacity toward tumor-associated antigens. In hepatocellular carcinoma, the leading targets are glypican-3, or GPC3, a cell surface proteoglycan abundantly expressed on malignant hepatocytes, and CD147, a transmembrane glycoprotein implicated in tumor invasion. GPC3-specific CAR-NK cells have been developed and validated in preclinical models, and anti-CD147 chimeric antigen receptors have demonstrated efficacy against hepatocellular carcinoma cells. A first-in-human phase 1 trial of induced pluripotent stem cell-derived CD19-directed CAR-NK cells in B-cell lymphoma has provided an important clinical template for the broader platform, demonstrating that off-the-shelf, genetically defined NK cell products can be manufactured and safely administered. The review notes, however, that head-to-head comparisons suggest CAR-T cells can outperform CAR-NK cells in some CAR-mediated effector functions, underscoring that the technology still has room to mature.

A parallel and rapidly evolving strategy involves bispecific and trispecific killer cell engagers, known as BiKEs and TriKEs. These antibody-like molecules physically bridge NK cells to tumor cells while simultaneously delivering activating signals. Trispecific killer engagers incorporating an interleukin-15 linker have been shown to direct NK cells toward CD33-positive targets while inducing persistence, in vivo expansion, and enhanced function. Tri-specific engagers targeting mesothelin have been used to steer NK cells toward lung cancer, and the platform is now being applied to liver cancer: a GPC3-targeted NK engager bispecific antibody has entered a phase 1/2a clinical trial in patients with hepatocellular carcinoma, and novel NKp46-based engagers targeting GPC3 have undergone preclinical characterization. Recent work has also produced therapeutic bispecific antibodies targeting CD16A on NK cells and GPC3 on tumor cells, and tetravalent bispecific engagers designed to activate NK cells against cancer without mediating fratricide, a key safety consideration when the targeting antigen is also expressed on the therapeutic cells themselves.

Combination strategies form another pillar of the review. The multikinase inhibitor sorafenib, a longstanding standard of care in advanced hepatocellular carcinoma, has been shown to perpetuate cellular anticancer effector functions by modulating crosstalk between macrophages and NK cells, and preclinical studies of sorafenib combined with memory-like NK cells have reported encouraging antitumor activity in models of the disease. Xenograft experiments mapping the signaling pathways engaged by combined sorafenib and NK cell therapy have reinforced the mechanistic rationale. Lenvatinib, a newer tyrosine kinase inhibitor, appears to activate antitumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment, creating a permissive setting for adoptive cell therapy. Immune checkpoint blockade is also being explored in combination with NK cell approaches, with single-cell RNA sequencing in humanized mice revealing antitumor potency of NK and CD8-positive T cells when PD-1 and TIGIT are co-targeted. Even oncolytic viruses have entered the picture, with an engineered measles virus shown to enhance the antitumor responses of adoptively transferred NKG2D-positive immune cells in hepatocellular carcinoma models.

The review is candid about the knowledge gaps that still separate laboratory promise from routine clinical benefit. The complex interplay between NK cells and the tumor microenvironment remains incompletely understood, particularly the roles of hepatic stellate cells and cancer-associated fibroblasts, which secrete chemokines such as CXCL5 that promote immunosuppressive signaling. The metabolic reprogramming of NK cells in the lipid-rich liver environment, the mechanosensory properties that govern NK cell function in dense tumor tissue, and the education and licensing processes that calibrate NK cell responsiveness all demand further study. Chronic alcohol consumption, a major risk factor for liver disease, has been shown to impair peripheral NK cell development by reducing interleukin-15 availability, adding another layer of complexity in a patient population where such exposures are common. The authors argue that resolving these questions is essential for optimizing NK cell immunotherapy and improving prognostic outcomes.

Nevertheless, the trajectory of the field is unmistakably upward. From the NK-92 cell line, whose three decades of use have shaped much of modern NK cell research, to iPSC-derived CAR-NK products and GPC3-directed engagers now in clinical trials, the toolkit for deploying natural killer cells against hepatocellular carcinoma has expanded dramatically in a short period. The review’s synthesis suggests that the coming years will be defined by rational combinations, pairing engineered NK cells with kinase inhibitors, checkpoint blockade, and metabolic interventions designed to neutralize the tumor microenvironment’s defenses. For a cancer that has long resisted immunotherapeutic advances and continues to claim hundreds of thousands of lives each year, the renaissance in NK cell biology may represent the most credible path yet toward durable, off-the-shelf immunotherapy for liver cancer, and the scientific foundation laid by this comprehensive analysis offers researchers a clear map of both the opportunities and the obstacles that lie ahead.

Subject of Research: Natural killer cell-based immunotherapy for hepatocellular carcinoma

Article Title: Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review

Article References: Widowati, W., Wargasetia, T. L., Sadri, B., Nainggolan, I. M., Azis, R., Rifana, S. D., Rismani, E., & Vosough, M. (2026). Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review. Medical Oncology, 43(11), Article 293. https://doi.org/10.1007/s12032-026-03393-5

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03393-5

Keywords: natural killer cells, hepatocellular carcinoma, immunotherapy, CAR-NK cells, tumor microenvironment, glypican-3, bispecific killer cell engagers, interleukin-15, liver cancer, adoptive cell therapy, NK cell dysfunction, sorafenib

Hand-foot syndrome, or PPE, is far more than a cosmetic nuisance. The condition typically begins with tingling, numbness and redness on the palms of the hands and soles of the feet, and can progress in severe cases to swelling, blistering, ulceration and intense pain that makes walking, gripping objects or even buttoning a shirt difficult. Because these symptoms strike exactly the functions patients rely on for daily life, PPE is a leading cause of dose reductions, treatment interruptions and outright abandonment of otherwise effective cancer regimens. Oncologists have long recognized it as a hallmark toxicity of certain targeted therapies and chemotherapy agents, but the true breadth of drugs implicated — and the timing of onset — has remained surprisingly poorly mapped.

To build that map, the researchers turned to FAERS, the FDA’s sprawling spontaneous reporting database, which collects adverse event submissions from healthcare professionals, manufacturers and patients across the United States. They extracted reports spanning the first quarter of 2004 through the first quarter of 2025, removed duplicate submissions, and then applied a family of statistical techniques known as disproportionality analysis. Rather than proving causation in the way a clinical trial would, disproportionality analysis asks a subtler question: does a particular drug appear in reports of a given side effect more often than would be expected by chance? Four complementary algorithms were used to answer that question — the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network and multi-gamma Poisson shrinkage. Requiring agreement across all four methods helps filter out spurious associations that can arise in self-reported data.

The results were striking in both their scale and their specificity. Protein kinase inhibitors — the targeted drugs that block enzymes driving cancer cell growth and tumor blood vessel formation — and antimetabolites, the classic chemotherapy agents that interfere with DNA and RNA synthesis, emerged as the dominant drug classes. Among individual agents, the oral kinase inhibitor regorafenib, the multi-kinase blocker sorafenib and the fluoropyrimidine prodrug capecitabine produced the strongest safety signals. These three drugs are mainstays of treatment for colorectal cancer, hepatocellular carcinoma, renal cell carcinoma and other hard-to-treat malignancies, meaning the toxicity burden is concentrated in some of oncology’s most vulnerable populations. The finding that hundreds of other drugs also appeared in PPE reports underscores that the syndrome is not confined to a short list of notorious culprits.

Perhaps the most clinically actionable discovery concerns timing. The vast majority of PPE cases — 83.4 percent — occurred within the first 90 days of starting treatment, with many surfacing within the initial weeks. This early-onset pattern carries an important message for oncology teams: the highest-risk window for hand-foot syndrome opens almost immediately after a patient begins therapy. The authors argue that this argues for proactive patient education at the very first prescription, so that patients recognize the earliest tingling or redness and report it before it escalates into blistering lesions. It also supports intensified skin assessment during the initial phases of treatment with high-risk drugs, when a timely dose adjustment can often prevent progression without compromising cancer control.

The analysis also uncovered differences in reporting patterns between female and male patients. For two drugs in particular — the HER2-targeted breast cancer therapy lapatinib and capecitabine — PPE signals were stronger in women. The researchers are careful to caution against overinterpreting this finding. Sex-related differences in spontaneous reports can arise from prescribing patterns, with some drugs used predominantly in diseases that affect one sex more than the other, as well as from possible biological factors such as differences in skin structure, drug metabolism or hormonal influences. Disentangling genuine biological susceptibility from the artifacts of who receives which drug and who reports which symptom remains an open challenge for pharmacovigilance, and the authors explicitly call for cautious interpretation and further study.

Mechanistically, hand-foot syndrome is thought to arise from the unique biology of the skin on the palms and soles. These regions are rich in eccrine sweat glands, experience high mechanical pressure and friction, and express high levels of the molecular targets — such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor — that protein kinase inhibitors are designed to block. When those signaling pathways are inhibited in the skin’s blood vessels, capillary damage and local inflammation can follow, and the repeated trauma of walking and gripping amplifies the injury. For antimetabolites like capecitabine, which is converted to 5-fluorouracil inside the body, the toxicity reflects the drug’s interference with rapidly dividing cells, with the concentration of the activating enzyme thymidine phosphorylase particularly high in palm and sole tissue. The convergence of drug exposure and mechanical stress explains why the syndrome has such a distinctive anatomical fingerprint.

The scale of the new study gives it particular weight in a field where much of the evidence comes from small clinical trials that may not capture rare or slowly accumulating toxicities. By pooling more than two decades of real-world reports, the analysis captures the experience of a far more diverse patient population than any single trial — patients with comorbidities, concurrent medications and varying ethnic backgrounds. At the same time, the authors and pharmacovigilance experts alike emphasize the inherent limitations of spontaneous reporting: not all adverse events are reported, reporting rates are influenced by media attention and litigation, and the database cannot establish how frequently PPE occurs relative to the total number of patients treated. Disproportionality signals are a starting point for hypothesis generation, not a verdict on causation.

Even with those caveats, the study’s implications for clinical practice are concrete. Oncologists prescribing regorafenib, sorafenib or capecitabine now have robust, data-driven backing for early and sustained skin monitoring, and the identification of 427 drugs with PPE reports should prompt awareness beyond the usual suspects, particularly as newer kinase inhibitors reach the market. For patients, the message is empowering: symptoms in the hands and feet during cancer treatment should never be dismissed as minor, because early recognition opens the door to dose modification, topical therapies, cooling measures and supportive care that can keep treatment on track. The research team concludes that enhanced vigilance and tailored monitoring schedules — matched to each drug’s risk profile and to the early onset window — are the most promising route to reducing the burden of this debilitating toxicity while preserving the anticancer benefits of the drugs patients depend on.

Subject of Research: Drug-induced palmar-plantar erythrodysaesthesia syndrome associated with antineoplastic agents identified through FDA adverse event reporting data

Article Title: Antineoplastic agent-induced palmar-plantar erythrodysaesthesia syndrome: insights from the FDA adverse event reporting system

Article References: Cheng, H., Li, Q., Hong, X., Zhang, Z., Chen, L., Yang, X., Wang, S., & Pan, W. (2026). Antineoplastic agent-induced palmar-plantar erythrodysaesthesia syndrome: insights from the FDA adverse event reporting system. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06547-0

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06547-0

Keywords: hand-foot syndrome, palmar-plantar erythrodysaesthesia, FAERS, pharmacovigilance, protein kinase inhibitors, capecitabine, regorafenib, sorafenib, antineoplastic agents, disproportionality analysis, adverse drug reactions, oncology